Delay of Systemic Therapy Confers a Survival Benefit in Patients with Stage IV Non-Small-Cell Lung Cancer.

Cancers (Basel) · 2025 · PMC12609030 · PMID 41228324

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Patients who received immunotherapy and had an ECOG-PS of 0 ( n = 73) showed a trend towards a worse mOS in the early TG (15 m; 95% CI = 4.32–25.68 vs. 20 m; 95% CI = 9.05–31.00).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.